EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epitranscriptomic RNA m 6 A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Mohammad Burhan Uddin iD, Zhishan Wang, Chengfeng Yang iD

Advanced Science · 2025-01 · 12 (4)

DOI: 10.1002/advs.202403936 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 11.12.2024. Verfasst von Mohammad Burhan Uddin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, North South University, Bashundhara, Dhaka, 1229, Bangladesh. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Significant advances in the development of new cancer therapies have given rise to multiple novel therapeutic options in chemotherapy, radiotherapy, immunotherapy, and targeted therapies. Although the development of resistance is often reported along with temporary disease remission, there is often tumor recurrence of an even more aggressive nature. Resistance to currently available anticancer drugs results in poor overall and disease‐free survival rates for cancer patients. There are multiple mechanisms through which tumor cells develop resistance to therapeutic agents. To date, efforts to overcome resistance have only achieved limited success. Epitranscriptomics, especially related to m 6 A RNA modification dysregulation in cancer, is an emerging mechanism for cancer therapy resistance. Here, recent studies regarding the contributions of m 6 A modification and its regulatory proteins to the development of resistance to different cancer therapies are comprehensively reviewed. The promise and potential limitations of targeting these entities to overcome resistance to various anticancer therapies are also discussed.

Schlagwörter

Stichwörter der Autor:innen

cancer stem cellcancer therapy resistanceepitranscriptomicsm6A modificationm6A regulator inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, North South University, Bashundhara, Dhaka, 1229, Bangladesh.
  • Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, 11794, USA.
  • Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.

ORCID-Profile: Mohammad Burhan Uddin, Chengfeng Yang

Förderung

  • NIEHS NIH HHS
  • Foundation for the National Institutes of Health

Zitieren

APA

Uddin, M. B., Wang, Z., & Yang, C. (2025). Epitranscriptomic RNA m 6 A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities. Advanced Science, 12(4). https://doi.org/10.1002/advs.202403936

Vancouver

Uddin MB, Wang Z, Yang C. Epitranscriptomic RNA m 6 A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities. Advanced Science. 2025;12(4). doi:10.1002/advs.202403936

BibTeX
@article{Uddin2025,
  author = {Uddin, Mohammad Burhan and Wang, Zhishan and Yang, Chengfeng},
  title = {Epitranscriptomic RNA m 6 A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {4},
  doi = {10.1002/advs.202403936}
}
Kostenlos starten →